Quarterly report pursuant to Section 13 or 15(d)

Grant Revenues (Details)

v3.7.0.1
Grant Revenues (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Grant received for preclinical activities from CPRIT $ 411,250 $ 411,250  
Deferred revenue $ 1,409,212   1,409,212  
Pelican Therapeutics, Inc. [Member]          
Grant received for preclinical activities from CPRIT     $ 15,200,000